Wrap Text
ASPI announces proposed public offering of common stock
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
WASHINGTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP
Isotopes" or the "Company"), an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in multiple industries, today announced
that it is commencing an underwritten public offering of shares of its common stock. The offering is
subject to market conditions, and there can be no assurance as to whether or when the offering may
be completed, or as to the actual size or terms of the offering.
Cantor and Lucid Capital Markets are acting as joint book-running managers for the offering.
The offering is being made pursuant to a shelf registration statement filed with the Securities and
Exchange Commission ("SEC") on October 14, 2025, which was immediately effective upon filing.
A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed
with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the offering, when available, may also
be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street,
6th Floor New York, New York 10022; Email: prospectus@cantor.com or Lucid Capital Markets, LLC,
570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities
nor will there be any sale of these securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or other jurisdiction.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development
of technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities
in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass
(light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging
healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and
heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements include, but are not limited to, statements regarding the Company's
anticipated public offering, including the completion of the public offering on the anticipated terms, if at
all, and other statements that are not historical facts. Forward-looking statements can be identified by
words such as "believes," "plans," "anticipates," "expects," "estimates," "projects," "will," "may," "might,"
and words of a similar nature. Because forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which
are outside our control. Our actual results, financial condition, and events may differ materially from
those indicated in the forward-looking statements based upon a number of factors. Forward-looking
statements are not a guarantee of future performance or developments. You are strongly cautioned that
reliance on any forward-looking statements involves known and unknown risks and uncertainties.
Therefore, you should not rely on any of these forward-looking statements. There are many important
factors that could cause our actual results and financial condition to differ materially from those indicated
in the forward-looking statements, including: the failure to obtain necessary regulatory and shareholder
approvals for the proposed acquisition of Renergen; disruption from the proposed acquisition of
Renergen making it more difficult to maintain business and operational relationships; significant
transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or
regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies
and projects undertaken by the Company; the potential impact of laws or government regulations or
policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties;
our ability to complete the proposed the construction and commissioning of our enrichment plant(s) or
to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability
to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any
current and future commercial arrangements; our ability to complete certain transactions and realize
anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights,
certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part
I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2024 and any amendments thereto and in the company's subsequent reports and filings
with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this
press release is based only on information currently available to us and speaks only as of the date on
which it is made. We undertake no obligation to publicly update any forward-looking statement, whether
as a result of new information, future developments or otherwise. No information in this press release
should be interpreted as an indication of future success, revenues, results of operation, or stock price.
All forward-looking statements herein are qualified by reference to the cautionary statements set forth
herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
15 October 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 15-10-2025 07:07:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
